Browsing Tag

Mergers & Acquisitions

420 posts

BioNTech To Acquire Cell-Therapy Mfg Facility, R&D Platform from Gilead
By

By
BioNTech, a Mainz, Germany-based immunotherapy company, has entered into a purchase agreement with Kite, part of Gilead Sciences, to acquire its solid-tumor neoantigen T cell receptor (TCR) R&D platform and…

AstraZeneca Completes $39-Bn Acquisition of Alexion
By

By
AstraZeneca has completed its $39-billion acquisition of Alexion Pharmaceuticals, a Boston-based bio/pharmaceutical company focused on rare diseases. The companies had announced the deal in December 2020. The acquisition marks AstraZeneca’s…

Global Pharma Briefs: News from Sanofi, GSK, Pfizer, AbbVie, Biogen
By

By
A roundup of news from China (Sparx Therapeutics), France (Sanofi), the UK (Pfizer, AbbVie, and Biogen) and the US (GSK, Nkarta, and USP). China Sparx Therapeutics To Build for Antibody…

AstraZeneca Gets UK OK for $39-Bn Acquisition of Alexion
By

By
The UK Competition and Markets Authority has cleared AstraZeneca’s proposed $39-billion acquisition of Alexion Pharmaceuticals, a Boston-based bio/pharmaceutical company focused on rare diseases. The clearance follows competition clearances in the…

Lilly Acquires Protomer Technologies in $1-Bn Deal
By

By
Eli Lilly and Company has acquired Protomer Technologies, a Pasadena, California-based technology company specializing in engineering protein therapeutics, in a $1-billion deal (inclusive of undisclosed milestone payments). Lilly currently holds…

Novo Nordisk To Acquire Prothena’s ATTR Drug Program in $1.2-Bn Deal
By

By
Novo Nordisk has agreed to acquire from Prothena, a Dublin, Ireland-based bio/pharmaceutical company, PRX004, an anti-amyloid immunotherapy, and Prothena’s broader ATTR amyloidosis program, in a $1.2-billion deal ($100 million upfront…

AstraZeneca Gets EU OK for Proposed $39-Bn Acquisition of Alexion
By

By
The European Commission (EC) has approved AstraZeneca’s proposed $39-billion acquisition of Alexion Pharmaceuticals, a Boston-based bio/pharmaceutical company focused on rare diseases. The clearance follows competition clearances in the US, Japan,…

Sanofi To Sell 16 Consumer Healthcare Products to Stada
By

By
Sanofi has agreed to sell a portfolio of 16 local and regional consumer healthcare brands in countries predominantly in Europe to Stada, a Bad Vilbel, Germany-based specialty pharma, generics, and…

GSK CEO Outlines Growth Plan, Demerger of OTC Business
By

By
GlaxoSmithKline (GSK) CEO Emma Walmsley outlined the company’s  growth strategy at an investor event earlier this week (June 23, 2021), which includes a revenue target of more than £33 billion…

Global Pharma Briefs: News from J&J, Novartis, Sanofi, and BMS
By

By
A roundup of news from Belgium (Legend Biotech, J&J), Canada (AbCellera), China (Frontera Therapeutics), Ireland (Horizon Therapeutics), Switzerland (Novartis), the UK (Exscientia), and the US (Sanofi, BMS, others). Belgium Legend…